NSB Trading Halt Pending Special Access Program Results
Key points
- Trading halt requested by NeuroScientific Biopharmaceuticals Ltd.
- Halt pending announcement of special access program results.
- Halt to end on release of announcement or May 27, 2026.
- Company unaware of reasons to deny the halt.
- Program results deemed material to the company.
Full summary
NeuroScientific Biopharmaceuticals Ltd (NSB) has requested a trading halt on the Australian Securities Exchange (ASX) to be effective until the release of an announcement regarding the results of a special access program. The halt is anticipated to conclude on the earlier of the announcement release or the resumption of normal trading on Wednesday, May 27, 2026. The company has confirmed that it is not aware of any reasons why the trading halt should not be granted and believes the program results are material to the company.
Outlook
NeuroScientific Biopharmaceuticals Ltd anticipates releasing material information regarding special access program results, pending the trading halt.
Summary generated by a large language model. Please interpret with care.